EPI Health, a Novan Company, Enters into Exclusive License Agreement with Sato Pharmaceutical Co., Ltd. for RHOFADE® in Japan
Retrieved on:
Wednesday, December 21, 2022
“Since 2017, our relationship with Sato has been a valuable component of our strategy and we are pleased to further deepen and expand our partnership with Sato through this license agreement.
Key Points:
- “Since 2017, our relationship with Sato has been a valuable component of our strategy and we are pleased to further deepen and expand our partnership with Sato through this license agreement.
- President and CEO of Sato Pharmaceuticals, Seiichi Sato, added, “We are pleased to significantly build on our longstanding relationship with Novan with this agreement.
- Sato will be responsible for obtaining regulatory approval in Japan and will have the right to access EPI Health’s U.S. dossier for RHOFADE.
- Sato will also have a right of first negotiation related to RHOFADE in certain other countries in the Asia Pacific region.